New treatment paradigm of combined raloxifene and conjugated estrogen for postmenopausal symptoms in VCD-induced menopausal rats
Conclusion We can conclude that appropriate RLX/CE combination could effectively be a promising alternative for the prevention of postmenopausal osteoporosis and VVA with no oncogenic risk.
Source: Alexandria Journal of Medicine - Category: Journals (General) Source Type: research
More News: Estradiol | Evista | General Medicine | Hormone Replacement Therapy | Hormones | Men | Menopause | Orthopaedics | Osteoporosis | Ovaries | Study | Women